Suppr超能文献

抗 MDA5 和抗氨酰-tRNA 合成酶抗体双阳性皮肌炎患者的临床特征和预后。

The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients.

机构信息

Peking University, China-Japan Friendship School of clinical medicine, Beijing, China.

Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China.

出版信息

Front Immunol. 2022 Aug 30;13:987841. doi: 10.3389/fimmu.2022.987841. eCollection 2022.

Abstract

OBJECTIVE

To explore the clinical features and prognoses of dermatomyositis (DM) associated with a double-positive anti-MDA5 and anti-aminoacyl-tRNA synthetase (anti-ARS) antibody presentation.

METHODS

We retrospectively analyzed 1280 consecutive patients with idiopathic inflammatory myopathy (IIM). Individuals with anti-MDA5 and anti-ARS antibodies (anti-MDA5+/ARS+) were compared to anti-MDA5-/ARS+ and anti-MDA5+/ARS- control individuals based on clinical, pulmonary radiological characteristics, treatment, and follow-up information.

RESULTS

Six individuals (0.47%) presented with anti-MDA5+/ARS+; of these, 2 (33.3%) were anti-PL-12+, 2 (33.3%) were anti-Jo-1+, 1 (16.7%) was anti-EJ+, and 1 (16.7%) was anti-PL-7+. Hallmark cutaneous manifestations, including Gottron's sign (100%), heliotrope rash (50%), mechanic's hand (66.7%), and skin ulcers (16.7%) were common. Anti-MDA5+/ARS+ patients tended to have higher ferritin levels (p = 0.038) than anti-MDA5-/ARS+ group, and higher CD4+ T-cell counts (p = 0.032) compared to the anti-MDA5+/ARS- group. Radiologically, NSIP with OP overlap was predominant (60%). Consolidation (60%), ground-glass attenuation (GGA) (80%), traction bronchiectasis (80%), and intralobular reticulation (100%) were common in anti-MDA5+/ARS+ individuals. All were diagnosed with ILD and 50% were categorized as RPILD. All patients received glucocorticoids combined with one or more immunosuppressants. Most (83.3%) had a good prognosis following treatment, but there was no difference in the survival rate between the three subgroups.

CONCLUSION

Presentation with anti-MDA5+/ARS+ DM was rare. The clinical and radiological characteristics of anti-MDA5+/ARS+ DM combined the features of anti-MDA5+ and anti-ARS+ individuals. Individuals with anti-MDA5+/ARS+ antibodies may respond well to glucocorticoid therapy; glucocorticoids combined with one or more immunosuppressants may be considered a basic treatment approach.

摘要

目的

探讨抗 MDA5 和抗氨酰-tRNA 合成酶(抗-ARS)抗体双重阳性的皮肌炎(DM)的临床特征和预后。

方法

我们回顾性分析了 1280 例特发性炎性肌病(IIM)连续患者。根据临床、肺部影像学特征、治疗和随访信息,将抗 MDA5 和抗 ARS 抗体阳性个体(抗 MDA5+/ARS+)与抗 MDA5-/ARS+和抗 MDA5+/ARS-对照组个体进行比较。

结果

6 例(0.47%)出现抗 MDA5+/ARS+;其中,2 例(33.3%)为抗 PL-12+,2 例(33.3%)为抗 Jo-1+,1 例(16.7%)为抗 EJ+,1 例(16.7%)为抗 PL-7+。常见的特征性皮肤表现包括 Gottron 征(100%)、向阳疹(50%)、技工手(66.7%)和皮肤溃疡(16.7%)。抗 MDA5+/ARS+患者的铁蛋白水平(p=0.038)高于抗 MDA5-/ARS+组,CD4+T 细胞计数(p=0.032)高于抗 MDA5+/ARS-组。影像学上,NSIP 与 OP 重叠为主(60%)。实变(60%)、磨玻璃影(GGA)(80%)、牵引性支气管扩张(80%)和小叶内网状影(100%)在抗 MDA5+/ARS+患者中常见。所有患者均诊断为ILD,50%为 RPILD。所有患者均接受糖皮质激素联合一种或多种免疫抑制剂治疗。治疗后大多数(83.3%)预后良好,但三组患者的生存率无差异。

结论

抗 MDA5+/ARS+DM 表现罕见。抗 MDA5+/ARS+DM 的临床和影像学特征结合了抗 MDA5+和抗 ARS+个体的特征。抗 MDA5+/ARS+抗体患者对糖皮质激素治疗反应良好;可考虑糖皮质激素联合一种或多种免疫抑制剂作为基本治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a7b/9468482/4de4494a314a/fimmu-13-987841-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验